Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2008 | 80 | 8 | 417-422
Tytuł artykułu

ε-Aminocaproic Acid (EACA)

Treść / Zawartość
Warianty tytułu
Języki publikacji
Słowa kluczowe
Opis fizyczny
  • Department of Vascular Surgery and Transplantation, Medical University, Białystok
  • Department of Vascular Surgery and Transplantation, Medical University, Białystok
  • Gabriel S, Maass TA: Ueber ε-aminocapronsäure. Ber Dtsch Chem Ges 1899; 32: 1266-72.[Crossref]
  • Okamoto S, Nakajima T, Okamoto U et al.: A suppresing effect of ε-amino-n-caproic acid and the bleeding of dogs, produced with the activation of plasmin in the circulatory blood. Keio J Med 1959; 8: 247-56.[Crossref]
  • Niewiarowski S: Untersuchungen über die hämostatische wirkung von ε-aminokapronsäure (EACA). Z Ges Inn Med 1965; 7: 323-25.
  • Westlund LE, Lunden R, Wallen P: Effect of EACA, PAMBA, AMCHA and AMBOCA on fibrynolysis induced by streptokinase, urokinase and tissue activator. Haemostasis 1982; 11: 235-41.
  • Łukasiewicz H, Niewiarowski S, Worowski K et al.: The plazmin inhibition by synthetic antifibrinolytic agents in relation to the type of substrate. Biochim Biophys Acta 1968; 159: 503-08.[Crossref]
  • Mathews II, Vanderhoff P, Castellino FJ et al.: Crystal structures of the recombinant kringle 1 domain of human plasminogen in complexes with the ligands ε-aminocaproic acid and trans-4-/aminomethyl/cyclohexane-1-carboxylic acid. Biochemistry, 1996; 35: 2567-76.
  • McClung WG: Interactions of fibrinolytic system proteins with lysine-containing surfaces. J Biomed Mater Res Part A. 2003; 66A: 795-801.[Crossref]
  • Okamoto S, Oshiba S, Mihara H et al.: Synthetic inhibitors of fibrynolysis: in vitro and in vivo action. Ann NY Acad Sci 1968; 146: 414-29.[Crossref]
  • Winn ES, Hu SP, Hochschwender SM et al.: Studies on the lysine-binding sites of human plasminogen. The effect of ligand structure on the binding of lysine analogs to plasminogen. Eur J Biochem 1980; 104: 579-86.[Crossref][PubMed]
  • Midura-Nowaczek K: Low molecular inhibitors of plasmin. Wiad Chem 1998; 52: 11-12.
  • Griffin JD, Ellman L: Epsilon-aminocaproic acid (EACA). Sem Thrombos Haemotas 1978; 5: 27-40.
  • Schwartz BS, Williams EC, Conlan et al.: Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency. Ann Int Med 1986; 105: 873-77.[Crossref]
  • Levy JH: Hemostatic agents and their safety. J Cardiothorac Vasc Anesth 1999; 13: 6-11.
  • Nielsen VG, Cankovic L, Steenwyk BK: ε-aminocaproic acid inhibition of fibrynolisis in vitro: should therapeutic concentration be reconside? Blood Coagulat Fibrynol 2007; 18: 35-39.[Crossref]
  • McNicol GP, Fletcher APAlkjaersig N et al.: Absorption, distribution, and excretion of ε-aminocapronic acid following oral or intravenous administration to man. J Lab Clin Med 1962; 59: 15-24.
  • Kostro B, Prokopowicz J, Serwatko A: Investigation on acute and chronic toxicity of epsilon-aminocapronic acid. Acta Physiol Pol 1964; 15: 372-79.
  • Frederiksen MC, Bowsher DJ, Ruo et al.: Kinetics of epsilon-aminocaproic acid distribution, elimination and antifibrinolytic effects in normal subjects. Clin Pharmacol Ther 1984; 35: 387-93.[Crossref]
  • Vander Salm TJ, Kaur S, Lancey RA et al.: Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovas Surg 1996; 112: 1098-1107.
  • Bonnett-Guerrero E, Sorohan JG, Canada AT et al.: Mythen MG. ε-aminocaproic acid plasma levels during cardiopulmonary by-pass. Anesth Analg 1997; 85: 248-51.
  • Slaughter TF, Faghih F, Greenberg CS et al.: The effects of epsilon-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery. Anesth Analg 1997; 85: 1221-26.[PubMed]
  • Kluger R, Olive DJ, Stewart AB et al.: Epsilonaminocaproic acid in coronary artery bypass graft surgery. Anesthesiology 2003; 99: 1263-69.[Crossref]
  • Kikura M, Levy JH, Tanaka KA et al.: A doublebind placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery. J Am Coll Surg 2006; 202: 216-22.
  • Munoz JJ, Birkmeyer NJ, Birkmeyer JD et al.: Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? A meta-analysis. Circulation 1999; 99: 81-89.[PubMed][Crossref]
  • Szczurek D, Andres J, Drwiła R et al.: The effects of tramaxamic acid and aprotinin on postoperative loss in coronary artery bypass surgery. Anestez Intens Terap 2001; 33: 247-49.
  • Choi TS, Greilich PE, Shi C et al.: Point-of-care testing for prethrombin time, but not activated partial thromboplastin time, correlates with laboratory methods in patients receving aprotinin or epsilon-aminocapronic acid while undergoing cardiac surgery. Am J Clin Pathol 2002; 117: 74-78.
  • Mangano DT, Tudor IC, Dietzel C: The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-65.[Crossref]
  • Suwalski G: Aprotinina - postępowanie antyfibrynolityczne w kardiochirurgii. Kardiol po Dypl 2006; 5: 10-21.
  • Bridges CR: Valid comparisons of antifibrinolytic agents used in cardiac surgery. Circulation 2007; 115: 2790-92.[Crossref][PubMed]
  • Brown J, Birkmeyer NJO, O'Conner GT: Meta-analysis comparing the effectiveness and adverse outcoms of antifibrinolytic agents in cardiac surgery. Circulation 2007; 115: 2801-13.[Crossref]
  • Pitts TO, Spero JA, Bontempo FA et al.: Acute renal failure due to high-grade obstruction following therapy with ε-aminocaproic acid. Am J Kidney Dis 1986; 8: 441-44.[PubMed]
  • Manjunath G, Fozailoff A, Mitcheson D et al.: Epsilon-aminocaproic acid and renal complications: case report and review of the literature. Clin Nephrol 2002; 58: 63-67.[PubMed][Crossref]
  • Worowski K: Synergestic antifibrinolytic action of the potato protease inhibitor and ε-aminocaproic acid. Acta Biol Acad Sci Hung 1976; 27: 125-28.
  • Smokovitz A, Kuintzis S, Kutsouris C et al.: The effects of intrafollicular iniection of plasmin and ε-aminocaproic acid on the ovulation in the ewe. Fibrinolysis 1989; 3: 227-30.
  • Nilsson IM, Sjoerdsma A, Waldenstrom J: Antifibrinolytic activity and metabolism of ε-aminocaproic acid in man. Lancet 1960; 18: 1322-26.[Crossref]
  • Vogt W, Schmiat G, Lynen R et al.: Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid. J Immunol 1975; 114: 671-77.
  • Wołosowicz N, Niewiarowski S: The in-vivo-effect of ε-aminocaproic acid (EACA) on human plasma fibrinolytic system. Thrombos Diathes Haemorrhag 1966; 15: 491-500.
  • Glick R, Green D, Tsao C et al.: Hig dose ε-aminocaproic acid prolongs the bleeding time and increase rebleeding and intraoperative hemorrhage in patients with subarachnoid hemorrhage. Neurosurgery 1981; 9: 398-401.
  • Green D, Tsao CH, Cerullo L et al.: Clinical and laboratory investigation of the effects of epsilon-aminocaproic acid on hemostasis. J Lab Clin Med 1985; 105: 321-27.
  • Sjoerdsma A, Hanson A: Determination of ε-aminocaproic acid in urine by means of high valtage electrophoresis. Acta Chem Scand 1959; 13: 2150-54.[Crossref]
  • Mc Nicol GP, Fletcher AP, Alkjaersig N et al.: Plasma amino acid chromatography with ion exchange resin loaded paper: assay of ε-aminocaproic acid. J Lab Clin Med 1962; 59: 7-12.
  • Farid NA: Fluorescamine use in high-performance liquid chromatographic determination of aminocaproic acid in serum. J Pharm Sci 1979; 68: 249-52.[Crossref][PubMed]
  • Lam S: High performance liquid chromatographic assay of Amicar ε-aminocaproic acid in plasma and urine after pre-column derivatization with o-phthalaldehyde for fluorescence detection. Biomed Chromatogr 1990; 4: 175-77.[Crossref]
  • Wołosowicz N, Niewiarowski S, Czerepko K: Method for determining ε-aminocaproic acid (EACA) in blood plasma, based on the antifibrinolytic properties of the compound. Thromb Diath Haemorrh 1964; 10: 309-16.
  • Wołosowicz N, Niewiarowski S: A simpll method of determining ε-aminocaproic acid (EACA) in urine. Clin Chim Acta 1965; 12: 555-57.[PubMed][Crossref]
  • Blix S: The euglobulin method for estimation of fibrinolytic activity in streptokinase-activated plasma. Scand J Clin Lab Invest 1962; 14: 528-32.[PubMed][Crossref]
  • Deutsch DG, Mertz ET: Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-96.[PubMed][Crossref]
  • Rosenberg AA, Peabody RA: Rapid estimation of fibrinogen in fibrinolytic and nonfibrinolytic states. Clin Chem 1972; 18: 666-68.
  • Steffen LW, Steffen BW: Improved method for measuring fibrinogen in plasma, with use of a plasmin inhibitor. Clin Chem 1976; 22: 381-83.[PubMed]
  • Stassano P, Musumeci A, Santise G et al.: Can ε-aminocaproic acid balance the off-pump bleeding advantage? Cardiovasc Surg 2003; 11: 219-24.[Crossref]
  • Greilich PE, Brouse CF, Rinder CS et al.: Effects of ε-aminocaproic acid and aprotinin on leuko-cyte-platelet adhesion in patients undergoing cardiac surgery. Anesthesiology 2004; 100: 225-33.[Crossref]
  • Johnson AJ, Skoza L: Chemical determination of epsilon aminocaproic acid, an inhibitor of plasminogen activation. Fed Proc 1961; 20: 59-62.
  • Czerepko K, Wołosowicz N: Analysis of aqueous mixtures of ε-aminocaproic acid and α,ε-diaminocaproic acid using ninhydryn. Talanta 1963; 10: 813-16.[Crossref]
  • Lammle B, Duckert F: Different assessment of plasmin with different substrates. In vitro alteration of plasmin, influence of ε-aminocaproic acid and tranexamic acid upon its activity. Thromb Haemost 1980; 43: 112-17.[PubMed]
  • Wu TP, Padmanabhan K, Tulinsky A et al.: The refined structure of the ε-aminocaproic acid complex of human plasminogen kringle 4. Biochemistry 1991; 30: 10589-94.
  • Anonick PK, Vasudevan J, Gonias SL: Antifibrinolytic activities of alpha-N-acetyl-L-lysine methyl ester, epsilon-aminocaproic acid, and tranexamic acid. Importance of kringle interactions and active site inhibition. Arterioscler Thrombos 1992; 12: 708-16.[Crossref]
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.